FY2025 EPS Estimates for Alumis Lowered by Cantor Fitzgerald

Alumis Inc. (NASDAQ:ALMS) – Investment analysts at Cantor Fitzgerald reduced their FY2025 EPS estimates for shares of Alumis in a research report issued to clients and investors on Thursday, March 20th. Cantor Fitzgerald analyst E. Schmidt now anticipates that the company will post earnings of ($5.36) per share for the year, down from their prior forecast of ($4.13). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Alumis’ current full-year earnings is ($8.51) per share.

Other analysts have also issued research reports about the company. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective (down previously from $19.00) on shares of Alumis in a report on Thursday, March 20th. Oppenheimer assumed coverage on Alumis in a research note on Thursday, January 30th. They issued an “outperform” rating and a $32.00 price target for the company. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Alumis currently has an average rating of “Buy” and a consensus price target of $26.00.

Alumis Price Performance

NASDAQ:ALMS opened at $3.78 on Monday. Alumis has a 52 week low of $3.18 and a 52 week high of $13.53. The firm has a 50 day moving average of $5.62 and a 200 day moving average of $8.49.

Institutional Trading of Alumis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ALMS. BNP Paribas Financial Markets acquired a new position in shares of Alumis in the third quarter valued at about $27,000. Wells Fargo & Company MN boosted its position in Alumis by 77.1% in the fourth quarter. Wells Fargo & Company MN now owns 8,779 shares of the company’s stock valued at $69,000 after buying an additional 3,823 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in Alumis in the 4th quarter worth approximately $79,000. MetLife Investment Management LLC purchased a new position in Alumis during the 3rd quarter worth approximately $89,000. Finally, Marshall Wace LLP acquired a new stake in Alumis during the 4th quarter valued at approximately $108,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.